Detection of fusion genes at the protein level in leukemia patients via the flow cytometric immunobead assay

Best Practice and Research: Clinical Haematology

Volumn 23, Issue 3, 2010, Pages 333-345

  Dekking, E ^a,b   Van Der Velden, V H J ^a   Bottcher S ^c   Bruggemann M ^c   Sonneveld, E ^d   Koning Goedheer, A ^d   Boeckx, N ^e   Lucio, P ^f   Sedek, L ^g   Szczepanski T ^g   Kalina, T ^h   Kovac, M ^h   Evans, P ⁱ   Hoogeveen, P G ^a   Flores Montero, J ^j   Orfao, A ^j   Comans Bitter, W M ^a   Staal, F J T ^a   Van Dongen, J J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Dynomics   (Netherlands)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^g MEDICAL UNIVERSITY OF SILESIA   (Poland)

^h CHARLES UNIVERSITY   (Czech Republic)

ⁱ ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^j CSIC   (Spain)

more..

Author keywords

BCR ABL; Fusion gene; Fusion protein; Immunobead assay; PML RARA

Indexed keywords

BCR ABL PROTEIN; HYBRID PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AF4; TRANSCRIPTION FACTOR CBFB; TRANSCRIPTION FACTOR E2A; TRANSCRIPTION FACTOR ETO; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR MLL; TRANSCRIPTION FACTOR MYH11; TRANSCRIPTION FACTOR PBX1; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER DIAGNOSIS; CANCER PATIENT; CELL LYSATE; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CONTROLLED STUDY; FLOW CYTOMETRIC IMMUNOBEAD ASSAY; FLOW CYTOMETRY; FUSION GENE; GENE STRUCTURE; GENETIC ANALYSIS; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA; PRIORITY JOURNAL; REVIEW;

ANTIBODIES; FLOW CYTOMETRY; HUMANS; IMMUNOASSAY; IMMUNOPHENOTYPING; LEUKEMIA; ONCOGENE FUSION; ONCOGENE PROTEINS, FUSION; PATHOLOGY, MOLECULAR;

EID: 78649528796     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2010.09.010     Document Type: Review

References (35)

1. F. Mitelman, B. Johansson, and F. Mertens The impact of translocations and gene fusions on cancer causation Nat Rev Cancer 7 2007 233 245
2. J.D. Rowley Chromosomal translocations: revisited yet again Blood 112 2008 2183 2189
3. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, J.W. Vardiman, WHO classification of tumours of haematopoietic and lymphoid tissues 4th ed. 2008 International Agency for Research on Cancer (IARC) Lyon
4. A. de Klein, A.G. van Kessel, and G. Grosveld A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia Nature 300 1982 765 767
5. C.R. Bartram, A. de Klein, and A. Hagemeijer Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia Nature 306 1983 277 280
6. A. Hermans, N. Heisterkamp, and M. von Linden Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia Cell 51 1987 33 40
7. J.J. van Dongen, E.A. Macintyre, and J.A. Gabert Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia Leukemia 13 1999 1901 1928
8. D. Grimwade, A. Biondi, and M.J. Mozziconacci Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Franais de Cytogénétique Hématologique, Groupe de Franais d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Molecular Cytogenetic Diagnosis in Haematological Malignancies" Blood 96 2000 1297 1308
9. T. Szczepański, C.J. Harrison, and J.J.M. Van Dongen Genetic aberations in pediactric acute leukemias and implication for patient management Lancet Oncol 11 2010 880 889
10. E. Anastasiadou, and J. Schwaller Role of constitutively activated protein tyrosine kinases in malignant myeloproliferative disorders: an update Curr Opin Hematol 10 2003 40 48
11. B.J. Druker, M. Talpaz, and D.J. Resta Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 2001 1031 1037
12. C.A. Schiffer BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia N Engl J Med 357 2007 258 265
13. E. Weisberg, P.W. Manley, and S.W. Cowan-Jacob Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia Nat Rev Cancer 7 2007 345 356
14. M.A. Sanz, D. Grimwade, and M.S. Tallman Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European Leukemia Net Blood 113 2009 1875 1891
15. M.S. Tallman, and J.K. Altman How I treat acute promyelocytic leukemia Blood 114 2009 5126 5135
16. M. van der Burg, T.S. Poulsen, and S.P. Hunger Split-signal FISH for detection of chromosome aberrations in acute lymphoblastic leukemia Leukemia 18 2004 895 908
17. J. Gabert, E. Beillard, and V.H. van der Velden Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program Leukemia 17 2003 2318 2357
18. J. Van Denderen, A. Hermans, and T. Meeuwsen Antibody recognition of the tumor-specific bcr-abl joining region in chronic myeloid leukemia J Exp Med 169 1989 87 98
19. J. van Denderen, D. van der Plas, and T. Meeuwsen Immunologic characterization of the tumor-specific bcr-abl junction in Philadelphia chromosome-positive acute lymphoblastic leukemia Blood 76 1990 136 141 (Pubitemid 20220802)
20. J. van Denderen, P. ten Hacken, and P. Berendes Antibody recognition of the tumor-specific b3-a2 junction of bcr-abl chimeric proteins in Philadelphia-chromosome-positive leukemias Leukemia 6 1992 1107 1112
21. J. van Denderen, P. ten Hacken, and P. Berendes Recognition of the ALL-specific BCR-ABL junction in P190bcr-abl by monoclonal antibody ER-FP1 Leukemia 8 1994 1503 1509
22. Berendes PB, Veenman JN, Van Denderen AC, et al. Recognition of tumor-specific gene products in cancer (Fusion protein dipstick patent). International patent 1998; PCT/NL98/00289.
23. Berendes PB, Veenman JN, Van Denderen AC, et al. The BCR-ABL dipstick assay: a simple and rapid method for detecting Ph+ leukemias. In: Berendes P, editor. Recognition of tumor-specific proteins in human cancer. Ph.D. Thesis. Rotterdam, The Netherlands: Department of Immunology, Erasmus University Rotterdam; 1997, p. 111-27.
24. Van Dongen JJM, Van der Velden VHJ, Berendes PB, et al. Recognition of tumour-specific gene products in cancer (Fusion protein bead patent). International Patent 2001; PCT/NL01/00.945.
25. F. Pane, F. Frigeri, and M. Sindona Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction) Blood 88 1996 2410 2414
26. J.V. Melo The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype Blood 88 1996 2375 2384
27. N. Boeckx, M.W. Jansen, and C. Haskovec Identification of e19a2 BCR-ABL fusions (mu-BCR breakpoints) at the DNA level by ligation-mediated PCR Leukemia 19 2005 1292 1295
28. A. Hochhaus, A. Reiter, and H. Skladny A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia Blood 88 1996 2236 2240
29. F. Weerkamp, E. Dekking, and Y.Y. Ng Euroflow consortium. Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients Leukemia 23 2009 1106 1117
30. V.H. van der Velden, H.B. Beverloo, and P.G. Hoogeveen A novel BCR-ABL fusion transcript (e18a2) in a child with chronic myeloid leukemia Leukemia 21 2007 833 835
31. E. Stein, B. McMahon, and H. Kwaan The coagulopathy of acute promyelocytic leukaemia revisited Best Pract Res Clin Haematol 22 2009 153 163
32. V. Liso, and J. Bennett Morphological and cytochemical characteristics of leukaemic promyelocytes Best Pract Res Clin Haematol 16 2003 349 355
33. M.W. Jansen, L. Corral, and V.H.J. Van der Velden Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement Leukemia 21 2007 633 641
34. C. Meyer, E. Kowarz, and J. Hofmann New insights to the MLL recombinome of acute leukemias Leukemia 23 2009 1490 1499
35. R. Pieters, M. Schrappe, and P. De Lorenzo A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial Lancet 370 2007 240 250